Research Article
Survival Outcomes and Care Equity among Patients with Advanced Breast Cancer in Auckland, New Zealand
| Parameter | Subgroups | | medOS(LQ-UQ) in months |
| Relapsed versus De novo | rMBC | 270 | 18.7 (7.0-39.1) | dnMBC | 118 | 18.9 (9.2-41.7) |
| Receptor subtypes | ER + PR + HER2- | 202 | 26.9 (11.4-44.7) | ER + PR-HER2- | 35 | 22.4 (8.9-39.3) | ER-PR- HER2+ | 31 | 13.8 (3.6-33.1) | ER + PR + HER2+ | 33 | 20.8 (13.2-44.8) | Triple negative | 73 | 10.6 (3.9-18.7) |
| Ethnicity | European | 232 | 18.9 (7.4-39.4) | Māori | 35 | 16.2 (7.0-38.9) | Asian | 50 | 26.3 (10.8-46.8) | Pacific peoples | 66 | 17.3 (6.9-39.0) |
| No. of lines of treatment | None | 53 | 3.3 (1.6-9.6) | 1 | 111 | 9.7 (4.7-31.7) | 2-3 | 145 | 20.8 (14.4-41.2) | 4-5 | 57 | 32.4 (25.3-43.8) | 6+ | 21 | 47.6 (32-59.1) |
|
|